Update shared on11 Sep 2025
Fair value Increased 21%Despite a decline in net profit margin, Coherus Oncology's significantly higher future P/E ratio reflects increased investor optimism, resulting in a raised consensus price target from $4.70 to $5.67.
What's in the News
- Coherus Oncology received a deficiency notice from Nasdaq after its common stock closed below $1.00 per share for 30 consecutive business days, putting it at risk of delisting.
- The company has 180 days to regain compliance by having its stock close at or above $1.00 per share for at least 10 consecutive business days.
- If compliance is not achieved, Coherus may qualify for a second 180-day compliance period by transferring to the Nasdaq Capital Market and meeting other listing requirements.
- Failure to regain compliance may result in delisting, though the company would have the right to appeal.
- Coherus intends to actively monitor its share price and consider options such as a reverse stock split to regain compliance.
Valuation Changes
Summary of Valuation Changes for Coherus Oncology
- The Consensus Analyst Price Target has significantly risen from $4.70 to $5.67.
- The Future P/E for Coherus Oncology has significantly risen from 32.99x to 42.45x.
- The Net Profit Margin for Coherus Oncology has significantly fallen from 16.06% to 14.17%.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.